Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study.
Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, Cosio DMO, Farrell M, Quiroz YT, Mormino EC, Buckley RF, Papp KV, Amariglio RA, Dewachter I, Ivanoiu A, Huijbers W, Hedden T, Marshall GA, Chhatwal JP, Rentz DM, Sperling RA, Johnson K. · 2019
Read Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. by Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, Cosio DMO, Farrell M, Quiroz YT, Mormino EC, Buckley RF, Papp KV, Amariglio RA, Dewachter I, Ivanoiu A, Huijbers W, Hedden T, Marshall GA, Chhatwal JP, Rentz DM, Sperling RA, Johnson K. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6547132.txt.
Introduction
Hanseeuw and co-authors track the two hallmark proteins of Alzheimer's disease in healthy older adults, writing in JAMA Neurology. Amyloid and tau build up in the brain years before symptoms start. The team followed 60 adults with normal thinking at entry, scanning each brain repeatedly for both proteins and testing cognition over time.
The speed of tau build-up in the lower temporal cortex matched the speed of cognitive decline. Amyloid build-up came first and predicted the later tau rise. That chain — early amyloid, then tau, then weaker cognition seven years on — explained the link between first scans and final scores. The authors say amyloid scans spot the disease early, while repeat tau scans best track its advance.
Catalog record
| CREATOR | Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, Cosio DMO, Farrell M, Quiroz YT, Mormino EC, Buckley RF, Papp KV, Amariglio RA, Dewachter I, Ivanoiu A, Huijbers W, Hedden T, Marshall GA, Chhatwal JP, Rentz DM, Sperling RA, Johnson K. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease By Bernard J. Hanseeuw, Rebecca A. Betensky, Heidi I. L. Jacobs, Aaron P. Schultz, Jorge Sepulcre, J. Alex Becker, Danielle M. Orozco Cosio, Michelle Farrell, Yakeel T. Quiroz, Elizabeth C. Mormino, Rachel F. Buckley, Kathryn V. Papp Published in: JAMA Neurology DOI: 10.1001/jamaneurol.2019.1424 ABSTRACT Key Points Question Is cognitive decline associated with amyloid-β or tau tangles accumulation? Findings In this cohort study that included 60 normal older adults with repeated positron emission tomography measures, the rate of tau accumulation in the inferior temporal neocortex was associated with the rate of cognitive decline. Amyloid accumulation was associated with subsequent tau accumulation, and this sequence of successive amyloid and tau changes in neocortex was found to mediate the association of initial amyloid with final cognition, measured 7 years later. Meaning Amyloid positron emission tomography is useful to detect early Alzheimer pathology; repeated tau positron emission tomography is useful to track disease progression. INTRODUCTION Alzheimer disease (AD) is a progressive cognitive disorder leading to dementia1 in which the brain gradually accumulates both amyloid-β (Aβ) and tau pathologies.2 Autopsy studies identified the early stages of Aβ and tau pathologies in individuals who were clinically normal during life, representing a preclinical stage of AD.3 Based on autopsy studies,4 the prevailing research hypothesis posits that Aβ precedes and accelerates neocortical tau pathology, which together precipitate cognitive decline. Molecular positron emission tomography (PET) tracers for Aβ5 and tau6 have made it possible to detect these pathologies in living individuals, including in clinically normal adults. However, previous longitudinal PET studies tracked either Aβ7,8 or tau9,10 accumulation; to our knowledge, a temporal sequence of Aβ and tau accumulation has not yet been evaluated. To observe the sequence of these pathologic events, we investigated the trajectories and temporal courses of longitudinal Aβ-PET and longitudinal tau-PET data. Improved understanding of these trajectories is needed to efficiently test therapeutic strategies designed to halt the progression of pathology and delay cognitive decline. While cognitive decline has been demonstrated in longitudinal studies of older adults with elevated levels of Aβ pathology at baseline,7,11,12,13 tau-PET may be more closely linked to neuronal injury and cognition.14,15,16 We therefore conducted a prospective natural history study to determine whether serial Aβ and tau measures were associated with concurrent and subsequent, serial measures of cognitive performance. METHODS Participants In this report, we analyzed data from the Harvard Aging Brain study, a longitudinal study of aging conducted at Massachusetts General Hospital, Boston. We reported prospective observations collected from January 1, 2010, to October 31, 2017, from 60 individuals who had normal cognition at study entry: global Clinical Dementia Rating of 0 and/or Mini Mental State Examination (MMSE) and Wechsler Logical Memory II delayed recall (LM) scores within normal range (MMSE ≥27 and LM ≥11 if ≥16 years of education and MMSE ≥25 and LM ≥7 otherwise). Exclusion criteria included drug or alcohol abuse, head trauma, and serious medical or psychiatric condition (Geriatric Depression Scale >10 of 30). Annual consensus meetings evaluated progression to mild cognitive impairment (MCI).17 The Partners Institutional Review Board has approved the Harvard Aging Brain study protocol, and participants provided written informed consent before undergoing any procedures. The participants analyzed in this report had multiple flortaucipir (FTP, also known as AV1451 or T807) and Pittsburgh compound B (PiB) PETs assessing tau and Aβ pathology, respectively. Study Design Longitudinal data (Figure 1) were acquired for PiB and cognition from 2010. Because FTP was not available before 2013, the initial FTP was defined as baseline (timet = 0, where subscript t indicates time in years), and the terms baseline FTPt = 0 and initial FTPt = 0 are equivalent. The initial PiB was acquired a median of 3 years before baseline and is termed initial PiBt = -3, with baseline PiBt = 0 referring to PiB at approximately the time of baseline FTPt = 0, with a median time difference of −1.1 months (range, −9.7 to 9.0). [Figure: Research Design and Serial Tau–Positron Emission Tomography (PET) Surface Images of an Illustrative ParticipantA, Baseline of this study was defined as the time of baseline FTP imaging (t = 0; where t indicates time in years from baseline). Change in flortaucipir (FTP) was evaluated between t = 0 and t = 2. Pittsburgh compound B (PiB) and cognitive data have been evaluated both between t = −3 and t = 0 and between t = 0 and t = 3. Parentheses mean that less than half the sample was observed. The brain images are of an illustrative participant with high PiB at baseline FTP-PET (ε4 noncarrier). Global Clinical Dementia Rating remained stable at 0 during the follow-up, but Preclinical Alzheimer Cognitive Composite z scores declined from 0.01 (t = 0) to −0.88 (t = 3). Note the progressive extension of FTP-PET signal from left entorhinal cortex to left temporal neocortex, posterior cingulate, and to the homologous regions in the right hemisphere. The FTP-PET images use a threshold set at standardized uptake value ratios (SUVr) of 1.05, with cerebral white matter as reference and partial volume correction.] Final PiBt = 2 was performed at the same time as final FTP t = 2, with a median time difference of 0.0 months (range, −6.3 to 23.4). Baseline cognitiont = 0 was evaluated within 6 months of baseline FTPt = 0, with a median time difference of −1.2 months (range, −5.9 to 5.5). Final cognitont = 3 was evaluated 11.8 months (range, −3.9 to 26.2) after final FTPt = 2. Participants had 2 or 3 FTP observations (n = 9) over a median follow-up of 26.0 months (range, 13.1-36.4). Participants had 2 to 5 PiB and 4 to 8 cognitive sessions. Pittsburgh compound B and cognition were measured in 2 successive periods: before and after baseline FTPt = 0. Pittsburgh compound B changes were measured before baseline for 36.4 months (range, 15.9-63.5) and after baseline for 24.4 months (range, 16.6-49.3). Cognitive changes were measured before baseline for 34.6 months (range, 4.3-48.8) and after baseline for 38.2 months (range, 23.2-50.5). In 10 participants without prebaseline PiB data, PiB change was assessed from PiBt = 0. Neuropsychologic Evaluation Participants in the Harvard Aging Brain study are evaluated annually with a battery of cognitive assessments, including tests of episodic memory, executive function, global cognition, and the Clinical Dementia Rating. For this study, we evaluated cognition using the Preclinical Alzheimer Cognitive Composite (PACC-96), a mean of z score performances on 4 tests sensitive to cognitive decline in at-risk individuals: MMSE, LM, Digit-Symbol Coding, and the Free and Cued Selective Reminding Test, which uses 3 versions with different items, each version repeated every 3 years.12 Molecular Imaging The 11C-PiB and F-18–FTP tracers were synthesized and administered onsite. Positron emission tomography images were acquired using a Siemens HR+ scanner. Both PiB and FTP measures were computed as standardized uptake value ratios (SUVr; 4 frames of 5 minutes: 80-100 minutes for FTP and 40-60 minutes for PiB) using cerebral white matter as the reference region8,18,19 because this reference provided more stable estimates of both PiB and FTP change10 (eAppendix in the Supplement).20 Positron emission tomography data were coregistered to each participant’s magnetic resonance imaging and segmented with Freesurfer, version 5